Cosibelimab
Based on 1 Customer Validation
Cosibelimab (CK-301) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy.
For research use only. We do not sell to patients.
- Purity : 99.90%
- CAS No.: 2216751-26-5
- Molecular Weight:144.64 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
B7-H1/PD-L1/CD274
In Vitro
Cosibelimab exhibits a functional Fc region that can induce antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity, mediating the killing of tumor cells by effector cells (such as natural killer cells)[2].
Cosibelimab blocks the interaction of PD-L1 with PD-1 and B7-1 receptors, reactivates T cells, restores the adaptive immunity and activates innate immunity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized PD-L1 Protein, Human can bind Cosibelimab. The EC50 for this effect is 18.75 ng/mL. -
Flow cytometric analysis of 106 Jurkat cells with Cosibelimab (HY-P99833, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 lambda1 (HY-P99992, blue) was used as the isotype control.
Product Details
-
CAS No. 2216751-26-5
-
Accession Q9NZQ7
-
Synonyms CK-301; TG-1501
-
Molecular Weight 144.64 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 lambda2
-
Recommend Isotype Controls
-
Format
-
Human IgG1 lambda2
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.90%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
References
[1]. Akintunde Akinleye, et al. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019 Sep 5;12(1):92. [Content Brief]
[2]. Clingan P, et al., Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. J Immunother Cancer. 2023 Oct;11(10):e007637. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)